The Prostate

We identify and validate accurate diagnostic biomarkers for prostate cancer through a systematic evaluation of DNA methylation alterations.

[1]  A. Haese*,et al.  Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer Prior to Initial Prostate Biopsy. , 2019, The Journal of urology.

[2]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  S. Srivastava,et al.  A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges , 2019, International journal of molecular sciences.

[4]  James L Mohler,et al.  NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  Á. Aytés,et al.  Epigenetic Regulation in Prostate Cancer Progression , 2018, Current Molecular Biology Reports.

[6]  Guojun Li,et al.  Clinical Significance of Peripheral Blood PCA3 Gene Expression in Early Diagnosis of Prostate Cancer , 2018, Translational oncology.

[7]  B. Kramer,et al.  Validation: a critical step in bringing biomarkers to clinical fruition. , 2017, Annals of Epidemiology.

[8]  N. Callander,et al.  Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma , 2017, The Journal of Biological Chemistry.

[9]  John M. Gaspar,et al.  DMRfinder: efficiently identifying differentially methylated regions from MethylC-seq data , 2017, BMC Bioinformatics.

[10]  F. Marchi,et al.  Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer , 2017, PloS one.

[11]  T. Zhu,et al.  Biomarkers identified for prostate cancer patients through genome-scale screening , 2017, Oncotarget.

[12]  H. Jin,et al.  DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer , 2017, Disease markers.

[13]  S. Poletajew,et al.  What Can Be Expected from Prostate Cancer Biomarkers A Clinical Perspective , 2017, Urologia Internationalis.

[14]  J. Bartlett,et al.  Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores , 2017, PloS one.

[15]  Patrick M M Bossuyt,et al.  Waste, Leaks, and Failures in the Biomarker Pipeline. , 2017, Clinical chemistry.

[16]  Zhiqiang Ma,et al.  Molecular insights of Gas6/TAM in cancer development and therapy , 2017, Cell Death & Disease.

[17]  I. Mills,et al.  The importance of DNA methylation in prostate cancer development , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  K. D. Sørensen,et al.  Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients , 2017, Scientific Reports.

[19]  Takafumi N. Yamaguchi,et al.  Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories , 2017, Nature Communications.

[20]  Alain Bergeron,et al.  Genomic hallmarks of localized, non-indolent prostate cancer , 2017, Nature.

[21]  A. Tewari,et al.  The Use of Biomarkers in Prostate Cancer Screening and Treatment. , 2017, Reviews in urology.

[22]  K. Kaulback,et al.  Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment. , 2017, Ontario health technology assessment series.

[23]  Geert Trooskens,et al.  Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. , 2016, European urology.

[24]  D. Calistri,et al.  GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications , 2016, Disease markers.

[25]  K. Kinzler,et al.  Evaluating the evaluation of cancer driver genes , 2016, Proceedings of the National Academy of Sciences.

[26]  F. Saad,et al.  The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements , 2016, Biomarkers in cancer.

[27]  Jeffrey M. Bhasin,et al.  MethylAction: detecting differentially methylated regions that distinguish biological subtypes , 2015, Nucleic acids research.

[28]  Jeffrey M. Bhasin,et al.  Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer. , 2015, Cell reports.

[29]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[30]  Zhaohui S. Qin,et al.  Detection of differentially methylated regions from whole-genome bisulfite sequencing data without replicates , 2015, Nucleic acids research.

[31]  Z. Altintas,et al.  Molecular biosensors: promising new tools for early detection of cancer , 2015 .

[32]  J. Vadgama,et al.  Epigenetics in breast and prostate cancer. , 2015, Methods in molecular biology.

[33]  Y. Bignon,et al.  Epigenetic modifications in prostate cancer. , 2014, Epigenomics.

[34]  B. Trock,et al.  Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. , 2014, The Journal of urology.

[35]  P. Febbo,et al.  A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.

[36]  K. D. Sørensen,et al.  Prognostic DNA Methylation Markers for Prostate Cancer , 2014, International journal of molecular sciences.

[37]  S. Clark,et al.  Prostate cancer epigenetic biomarkers: next-generation technologies , 2014, Oncogene.

[38]  G. Metzger,et al.  Evaluation of protein biomarkers of prostate cancer aggressiveness , 2014, BMC Cancer.

[39]  T. H. van der Kwast,et al.  Novel Multiplex MethyLight Protocol for Detection of DNA Methylation in Patient Tissues and Bodily Fluids , 2014, Scientific Reports.

[40]  Simendra Singh.  Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death , 2014, Cancer Chemotherapy and Pharmacology.

[41]  Y. Ge,et al.  The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies , 2014, Tumor Biology.

[42]  K. D. Sørensen,et al.  DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Ward,et al.  PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. , 2013, The Journal of urology.

[44]  Kyung Park,et al.  Epigenomic alterations in localized and advanced prostate cancer. , 2013, Neoplasia.

[45]  Wim Van Criekinge,et al.  Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. , 2013, The Journal of urology.

[46]  Robert D. Lieberthal,et al.  Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending. , 2013, American health & drug benefits.

[47]  Martin J. Aryee,et al.  DNA Methylation Alterations Exhibit Intraindividual Stability and Interindividual Heterogeneity in Prostate Cancer Metastases , 2013, Science Translational Medicine.

[48]  L. Luo,et al.  GSTP1 negatively regulates Stat3 activation in epidermal growth factor signaling , 2012, Oncology letters.

[49]  J. Ioannidis.  Biomarker failures. , 2013, Clinical chemistry.

[50]  S. Murphy,et al.  Methylation-specific PCR. , 2013, Methods in molecular biology.

[51]  O. Brawley,et al.  Trends in prostate cancer in the United States. , 2012, Journal of the National Cancer Institute. Monographs.

[52]  K. V. Donkena,et al.  Global Methylation Profiling for Risk Prediction of Prostate Cancer , 2012, Clinical Cancer Research.

[53]  Shaffi Ahamed Shaikh,et al.  Measures Derived from a 2 x 2 Table for an Accuracy of a Diagnostic Test , 2011 .

[54]  Gavin Sherlock,et al.  DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. , 2011, Genome research.

[55]  E. Giovannucci,et al.  Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis , 2011, British Journal of Cancer.

[56]  J. Ku,et al.  Methylation-specific PCR. , 2011, Methods in molecular biology.

[57]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[58]  R. Watson,et al.  The epigenome as a therapeutic target in prostate cancer , 2010, Nature Reviews Urology.

[59]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[60]  K. Pienta,et al.  GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. , 2010, Neoplasia.

[61]  Hafiz Ahmed.  Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples , 2010, Biomarkers in cancer.

[62]  J. Issa,et al.  Cancer Epigenetics , 2010, CA: a cancer journal for clinicians.

[63]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[64]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[65]  V. Beneš,et al.  The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. , 2009, Clinical chemistry.

[66]  G. Haas,et al.  Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer , 2009, BJU international.

[67]  J. Cheville,et al.  Hypermethylation of Genes for Diagnosis and Risk Stratification of Prostate Cancer , 2009, Cancer investigation.

[68]  B. Leiby,et al.  Stat3 promotes metastatic progression of prostate cancer. , 2008, The American journal of pathology.

[69]  Seongjoon Koo,et al.  PCA3: a molecular urine assay for predicting prostate biopsy outcome. , 2008, The Journal of urology.

[70]  M. Esteller.  Epigenetics in cancer. , 2008, The New England journal of medicine.

[71]  G. Haas,et al.  The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. , 2008, The Canadian journal of urology.

[72]  A. Mazumder,et al.  Quantitative, spatial resolution of the epigenetic field effect in prostate cancer , 2008, The Prostate.

[73]  Gerben Menschaert,et al.  PubMeth: a cancer methylation database combining text-mining and expert annotation , 2007, Nucleic Acids Res..

[74]  Kirsten L. Greene,et al.  Chapter 33 – Molecular Basis of Prostate Cancer , 2008 .

[75]  Ishtiaq Rehman,et al.  Molecular Detection of Localized Prostate Cancer Using Quantitative Methylation-Specific PCR on Urinary Cells Obtained Following Prostate Massage , 2007, Clinical Cancer Research.

[76]  R. Henrique,et al.  Epigenetic Markers for Molecular Detection of Prostate Cancer , 2007, Disease markers.

[77]  P. Burns,et al.  DNA methylation of GSTP1 as biomarker in diagnosis of prostate cancer. , 2007, Urology.

[78]  Christian B. Woods,et al.  Analysis of repetitive element DNA methylation by MethyLight , 2005, Nucleic acids research.

[79]  L. Castello,et al.  Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor , 2005, Journal of cellular physiology.

[80]  A. D. De Marzo,et al.  Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. , 2004, European urology.

[81]  Rui Henrique,et al.  Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. , 2004, European urology.

[82]  Jeanne Kowalski,et al.  Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate Cancer , 2004, Cancer Research.

[83]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia , 2004, The Journal of pathology.

[84]  A. Spicer,et al.  A Hyaluronan Binding Link Protein Gene Family Whose Members Are Physically Linked Adjacent to Chrondroitin Sulfate Proteoglycan Core Protein Genes , 2003, Journal of Biological Chemistry.

[85]  David F Ransohoff,et al.  Challenges and opportunities in evaluating diagnostic tests. , 2002, Journal of clinical epidemiology.

[86]  J. Herman,et al.  Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[87]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[88]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[89]  W. Isaacs,et al.  CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[90]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[91]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.